Poster-Disease-modifying Therapy
October 25, 2021
Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Four Data
Background: Ocrelizumab (OCR) is a humanized, monoclonal antibody targeting CD20+ B cells and is approved for treatment of relapsing...
Poster-Disease-modifying Therapy
October 25, 2021
Real-Life Experience with Ocrelizumab in Older Patients at an Academic MS Center
Background: Ocrelizumab (OCR) is a B-Cell depleting humanized monoclonal antibody FDA-approved for treatment of relapsing remitting...
Poster-Disease-modifying Therapy
October 25, 2021
Acapella: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Four Data
Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for the treatment of relapsing remitting (RRMS) and...
Poster-Disease-modifying Therapy
October 25, 2021
Effect of Age on the Change of Lymphocytes and Immunoglobulins during Treatment with Ocrelizumab or Rituximab for Multiple Sclerosis and Related Disorders
Background: Depletion of B lymphocytes is a known therapeutic strategy for multiple sclerosis (MS) and related disorders. Ocrelizumab (OCR)...
Poster-Disease-modifying Therapy
October 25, 2021
Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study
Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...
Poster-Disease-modifying Therapy
October 25, 2021
Adherence to Multiple Sclerosis Disease Modifying Therapies Using Pharmacy Quality Alliance Criteria and Medical Costs or Hospitalizations in an Administrative Database.
Background: Evidence is needed that adherence to disease-modifying therapies (DMT) for multiple sclerosis (MS) can reduce total medical...
Poster-Disease-modifying Therapy
October 25, 2021
Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World
Background: Siponimod was approved in the United States (US) in March 2019 for patients with relapsing forms of Multiple Sclerosis (MS)....
Poster-Disease-modifying Therapy
October 25, 2021
Characterization of Treatment-Naïve Patients with Multiple Sclerosis Newly Initiating Disease-Modifying Therapy
Background: The treatment landscape for multiple sclerosis (MS) continues to evolve and many disease-modifying therapies (DMTs) with...
Poster-Disease-modifying Therapy
October 25, 2021
Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies
Background: Switching of disease-modifying therapies (DMTs) for treatment of multiple sclerosis (MS) is driven by many factors that are not...
Poster-Disease-modifying Therapy
October 25, 2021
Multiple Sclerosis Disease Modifying Therapies Adherence and Total Medical Costs Among Women with Maternity Services Using Administrative Data.
Background: Women with multiple sclerosis (MS) who become pregnant and utilize maternity services may find their use of disease-modifying...